Medpace Holdings, Inc.
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $13.14B |
| Revenue | $2.68B |
| Net Income | $460M |
| Total Assets | $2.13B |
| Net Assets | $598M |
| Employees | 6,200 |
| Value | |
| P/E | 28.54x |
| P/B | 21.96x |
| PEG | 3.53x |
| P/S | 4.91x |
| EV/EBITDA | 21.79x |
| FCF Yield | 5.61% |
| Profitability | |
| ROE | 76.95% |
| ROA | 21.62% |
| Op. Margin | 21.02% |
| Revenue Growth | 26.50% |
| Earnings Growth | 8.09% |
| Financial Health | |
| Debt Ratio | 255.94% |
| Total Debt | $146M |
| FCF | $738M |
| Cash | $653M |
| Current Ratio | 0.85x |
| Net Debt/EBITDA | -0.87x |
| Performance | |
| 1Y Return | 52.01% |
| 1M Return | 9.58% |
| From 52W High | -26.84% |
| 1Y MDD | -36.61% |
| Trading | |
| Volume | 213,191 shares |
| Trading Value | $97M |
| Per Share | |
| EPS | $15.95 |
| BPS | $16.23 |
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.